Aproximación a la situación epidemiológica en Argentina de la infección perinatal por estreptococo beta hemolítico del grupo B (EGB)

Lomuto, Celia; Santos, Norberto; Messina, Analía; Fatur, Daniel; Nigri, Carolina; Queiruga, Marta.
Rev. Hosp. Matern. Infant. Ramon Sarda ; 25(1): 13-19, 2006. tab, graf
Artigo em Espanhol | LILACS | ID: lil-433114

Documentos relacionados

  1. Every Country, Every Family: Time to Act for Group B Streptococcal Disease Worldwide.
  2. Oral delivery of a Streptococcus agalactiae vaccine to Nile tilapia (Oreochromis niloticus) using a novel cationic-based nanoemulsion containing bile salts.
  3. Group B Streptococcal Vaccine - Sisyphus Reconciled.
  4. Cluster detection with random neighbourhood covering: Application to invasive Group A Streptococcal disease.
  5. Serotyping of invasive and colonizing group B Streptococcus (GBS) isolates at selected hospitals in Sri Lanka: a multicenter study.
  6. A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases.
  7. Women's knowledge of and attitudes towards group B streptococcus (GBS) testing in pregnancy: a qualitative study.
  8. Genomics-driven prophylactic measures to increase streptococcosis resistance in tilapia.
  9. Immune response and protective efficacy of mannosylated polyethylenimine (PEI) as an antigen delivery vector, administered with a Streptococcus agalactiae DNA vaccine in Nile tilapia (Oreochromis niloticus).
  10. A nanocarrier immersion vaccine encoding surface immunogenic protein confers cross-immunoprotection against Streptococcus agalactiae and Streptococcus iniae infection in tilapia.